Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neurofilament heavy polypeptide (NEFH) is a **type IV intermediate filament protein** and a core component of neurofilaments, which along with NEFL (light) and NEFM (medium) subunits, form the major cytoskeletal elements of neurons[2][5][6]. NEFH is essential for the **maintenance of neuronal shape and axonal caliber**, supporting fast axonal transport and contributing to the mechanical strength and stability of axons[2][5][6]. It is highly phosphorylated in axons, and its phosphorylation status modulates neurofilament spacing and axonal properties[2]. NEFH is not an enzyme, receptor, transporter, or typical pharmacological target, but instead is a **structural protein**. Mutations in NEFH are associated with **neurodegenerative diseases**, including Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis (ALS)[3][5][7]. Levels of NEFH (or its phosphorylated forms) in cerebrospinal fluid or blood are widely used as a **biomarker** for neuronal injury and axonal degeneration in clinical and research settings[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neurofilament heavy polypeptide (NEFH).